Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Surveillance AFter Extremity Tumor surgerY
NCT03944798 · View on ClinicalTrials.gov ↗
Study Summary
Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patients. Therefore, careful post-operative surveillance is an integral element of patient care. However, the detection of metastases does not necessarily affect long-term survival and may negatively impact quality of life. Surveillance strategies have not been well researched and have been identified as the top research priority in the extremity sarcoma field. Using a 2X2 factorial design to maximize efficiency and reduce overall trial costs, the SAFETY trial randomized 310 extremity soft-tissue sarcoma (STS) patients to determine the effect of surveillance strategy on overall patient survival after surgery for a STS of the extremity by comparing the effectiveness of both surveillance frequency (every 3 vs. every 6 months) and imaging modality (CT scans vs. chest radiographs).
Conditions Studied
Interventions
- OTHER Frequency: Every 3 Months
- OTHER Frequency: Every 6 Months
- OTHER Imaging Modality: Chest Radiograph (CXR)
- OTHER Imaging Modality: Chest CT
Study Locations (20)
New York
- Albany Medical Center — Albany
- NYU Langone Orthopaedic Hospital/Perlmutter Cancer Center — New York
- Montefiore Medical Center — The Bronx
Other
- Hospital Universitario Austral — Buenos Aires
- LKH - Universitätsklinikum Graz — Graz
- Cliniques Universitaires Saint-Luc — Brussels
California
- University of California Davis Medical Center — Sacramento
Connecticut
- Hartford HealthCare — Hartford
Florida
- University of Florida Health Shands Hospital — Gainesville
Illinois
- UChicago Medicine — Chicago
Indiana
- Parkview Cancer Institute — Fort Wayne
Iowa
- Holden Comprehensive Cancer Center — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03944798
The ClinicalTrials.gov registry entry for NCT03944798 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is McMaster University, which has 13 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 4 interventions — of which Frequency: Every 3 Months is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03944798 reports 20 study locations spanning 16 distinct geographic areas — top geographies include New York, Other, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03944798 about?
NCT03944798 is a clinical study titled "Surveillance AFter Extremity Tumor surgerY". Following treatment for a primary extremity sarcoma, patients remain at risk for the development of local and systemic disease recurrence. Metastasis (distant recurrence) to the lung is the most frequent single location of disease recurrence in sarcoma patients, occurring in almost half of all patie...
What is the current status of trial NCT03944798?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 310 participants. The study started on 2019-11-19. Estimated completion is 2027-12.
What conditions does trial NCT03944798 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Lung Metastases. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03944798?
The interventions under investigation include: Frequency: Every 3 Months (OTHER), Frequency: Every 6 Months (OTHER), Imaging Modality: Chest Radiograph (CXR) (OTHER), Imaging Modality: Chest CT (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03944798?
This trial is sponsored by McMaster University, which has 13 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03944798 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.